Braeburn Pharmaceuticals

Braeburn Pharmaceuticals, an Apple Tree Partners company, develops and commercializes innovative medical products. Upon approval, the company’s first product will be Probuphine®, a buprenorphine implant currently under FDA priority review for the maintenance treatment of opioid dependence. Braeburn’s executive team has decades of experience successfully bringing blockbuster pharmaceuticals and medical devices to market, as well as a deep understanding of clinical development and quality assurance processes. Apple Tree Partners is a venture capital firm that seeks to in-license and/or acquire products to build complementary pharmaceutical, medical device, and technology-enabled health care services companies.